- During the placebo-controlled period, at week 16, patients taking OTEZLA 30 mg BID achieved a greater mean decrease in BASDAI score vs patients taking placebo (-1.53 vs -0.91;
P = 0.0173)1†
This site is intended for healthcare professionals outside the U.S.
PALACE 1-3 pooled analysis. LOCF; includes patients randomized to OTEZLA 30 mg BID or placebo at baseline.
Data as observed; includes patients who were randomized to OTEZLA 30 mg BID at baseline and remained on treatment for 52 weeks.
P = 0.0002 vs placebo.
Pooled patient data from PALACE 1-3; patients with axial involvement, as deemed by the investigator upon clinical assessment; BASDAI score was an exploratory measure in the subset of patients with axial involvement and a baseline BASDAI score of ≥4 (n = 454); BASDAI mean scores at BL were 6.6 for OTEZLA 30 mg BID and 6.4 for placebo.
BASDAI, Bath Ankylosing Disease Activity Index; BL, baseline; LOCF, last observation carried forward; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
Reference: 1. Mease PJ, Marzo-Ortega H, Poder A, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in BASDAI in Patients With Psoriatic Arthritis: Pooled Results From 3 Phase III, Randomized, Controlled Trials. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK.
Please choose a country